Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Stock Information for Edesa Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Edesa Biotech Inc.

Edesa Biotech Announces Pricing of $25.0 Million Public Offering
Edesa Biotech Announces Proposed Public Offering
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.